Skip to content

MedCrypt

MedCrypt builds embedded cybersecurity and FDA-compliance software that helps medical device manufacturers secure connected devices and pass premarket regulatory review.

Visit Website ↗ + Add to Compare Claim This Company
70/100Meaningful Innovator

Overview

Founded in 2016 in San Diego, MedCrypt provides embedded cryptography, vulnerability management, and regulatory-support software purpose-built for medical device manufacturers navigating FDA premarket cybersecurity submission requirements. Its platform helps device makers build in security controls during development and maintain a security intelligence feed for post-market monitoring, addressing both engineering and compliance needs in a single product line.

MedCrypt has attracted strategic investment from major medical device and healthcare technology players — Johnson & Johnson Innovation, Intuitive Ventures, and Dexcom Ventures — bringing total funding to more than $36 million. That roster of corporate strategic investors, all themselves medical device manufacturers or adjacent healthcare technology companies, is a notable independent signal that the largest players in the space see value in MedCrypt’s approach. The company also reports a 100% FDA premarket submission approval rate for devices using its platform, a figure that is vendor-stated but consistent across multiple independent trade press reports.

MedCrypt’s differentiator is narrowly focusing on the FDA’s specific medical device cybersecurity premarket guidance rather than offering generic IoT security, giving device manufacturers a more direct path through regulatory approval alongside embedded security controls.

Innovation Matrix Assessment

Innovation Velocity 7/10

MedCrypt has expanded from embedded cryptography into a broader security-intelligence platform over nearly a decade, tracking FDA's evolving premarket cybersecurity guidance as it has tightened.

Operational Value 8/10

By combining embedded security controls with direct support for FDA premarket submissions, MedCrypt reduces both the engineering burden and regulatory risk for device manufacturers — a high-value combination for a heavily regulated industry.

Market Momentum 7/10

Strategic investment from J&J Innovation, Intuitive Ventures, and Dexcom Ventures — all major medical device or healthcare technology companies rather than pure financial investors — is a meaningful, independently verifiable signal of industry validation.

Category Disruption 6/10

MedCrypt is a category specialist rather than a category-definer; medical device cybersecurity compliance software is an established niche, though MedCrypt has a leading position within it.

Real-World Efficacy 6/10

The claimed 100% FDA submission approval rate is vendor-stated but repeated consistently across independent press coverage over multiple years, which lends it more credibility than a one-off marketing claim, even without a formal independent audit.

Enduring Relevance 8/10

FDA cybersecurity requirements for medical devices continue to tighten, and the connected medical device attack surface keeps growing, so this category will remain relevant over the next several years.

Why CISOs Should Care

Healthcare and medical device security leaders can use MedCrypt to reduce both the risk of FDA submission delays and the risk of post-market vulnerabilities in connected devices, addressing engineering and compliance simultaneously.

What Makes It Different

MedCrypt is built specifically around FDA's medical device premarket cybersecurity guidance rather than being generic IoT or embedded-systems security software adapted to healthcare.

The Matrix Verdict

70/100 — MEANINGFUL INNOVATOR

MedCrypt qualifies as a Meaningful Innovator: a decade-established, strategically well-backed specialist with real corporate validation from major medical device manufacturers, operating in a narrow but increasingly critical regulatory niche.

Editorial Note: Claims vs. Verified Findings

Strategic corporate investment is independently verifiable; the 100% FDA approval rate and specific customer counts are vendor-reported figures repeated in press coverage but not independently audited.

Sources